Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix Inc. was a biopharmaceutical company whose news centered on oncology drug development, regulatory interactions, governance actions, and capital-structure disclosures before its acquisition by Jazz Pharmaceuticals in April 2025. The company’s most advanced program was dordaviprone, also known as ONC201, in development for H3 K27M-mutant glioma, and its pipeline also included ONC206 research evaluating safety and pharmacokinetics.
Recurring Chimerix updates included FDA review milestones, clinical-development disclosures, operating and financial results, material agreements, and equity-compensation actions such as inducement grants under Nasdaq Listing Rule 5635(c)(4).
Chimerix (NASDAQ: CMRX), a biopharmaceutical firm, announced its participation in two investor conferences in September. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 1:00 p.m. ET, where Chimerix will present a corporate overview and hold investor meetings. Additionally, management will engage in investor meetings at the Cantor Fitzgerald Virtual Healthcare Conference on September 16. A live audio webcast of the presentation will be available on their Investor Relations website.
Chimerix focuses on developing innovative treatments, including DSTAT for acute lung injury and BCV as a countermeasure for smallpox.
Chimerix (NASDAQ: CMRX) will host a live conference call and audio webcast on August 10, 2020, at 8:30 a.m. ET, to discuss its second-quarter financial results ending June 30, 2020, and provide a business overview. The call can be accessed by dialing (877) 354-4056 (domestic) or (678) 809-1043 (international). Chimerix focuses on developing innovative medicines for cancer and serious diseases, with clinical-stage programs including dociparstat sodium (DSTAT) for acute lung injury related to COVID-19 and brincidofovir (BCV) for smallpox.
Chimerix (NASDAQ: CMRX) appointed Dr. Allen Melemed as Chief Medical Officer, aiming to leverage his extensive experience in oncology. His role is crucial as Chimerix prepares for a Phase 3 trial for dociparstat sodium (DSTAT) in acute myeloid leukemia (AML) and a Phase 2/3 trial for COVID-19 acute lung injury. DSTAT shows promise in improving survival rates in AML patients and managing inflammation in COVID-19. Dr. Melemed has over 20 years of experience in clinical development at Eli Lilly, contributing to significant oncology drugs.
Chimerix (NASDAQ: CMRX) announced that CEO Mike Sherman will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 9:30 a.m. ET. The presentation will be available live on the Investor Relations section of their website and archived for 90 days. Chimerix is focused on developing innovative medicines for serious diseases, with ongoing clinical programs for dociparstat sodium (DSTAT), aimed at treating COVID-19, and brincidofovir (BCV) for smallpox. DSTAT is undergoing a Phase 2/3 trial to assess its efficacy in patients with severe COVID-19.
Summary not available.